<DOC>
	<DOCNO>NCT02961491</DOCNO>
	<brief_summary>The purpose sub-study provide expand access AZEDRA ( Ultratrace Iobenguane I 131 ) evaluate safety tolerability AZEDRA subject iobenguane-avid malignant and/or recurrent pheochromocytoma/paraganglioma ( PPGL ) .</brief_summary>
	<brief_title>Expanded Access Program Ultratrace Iobenguane I131 Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma</brief_title>
	<detailed_description>MIP-IB12B , pivotal phase 2 study evaluate efficacy safety AZEDRA patient malignant relapsed/refractory PPGL , complete anticipated enrollment . The purpose sub-study , MIP-IB12B-EAP , provide expand access AZEDRA newly enrol subject iobenguane-avid metastatic and/or recurrent PPGL collect additional safety data .</detailed_description>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Able willing provide inform consent/assent comply protocol requirement Documented diagnosis either pheochromocytoma paraganglioma confirm histology supportive data ( e.g . abnormal MIBG diagnostic study elevate tumor marker ) Ineligible curative surgery PPGL Failed prior therapy PPGL alternative indicate therapy available Have definitive tumor avidity confirm AZEDRA dosimetry dose Life expectancy least 6 month per physician Pregnant nursing female Men woman childbearing potential unwilling use medically acceptable form contraception time consent 6 month follow last therapeutic dose AZEDRA Active CNS lesion CT/MRI within 3 month inform consent NYHA class IV heart failure , unstable angina pectoris clinically significant cardiac arrhythmia pose risk syncope cardiac arrest Prior systemic radiotherapy result marrow toxicity within 3 month first AZEDRA therapeutic dose Prior iobenguane I 131 therapeutic exposure within 12 week first plan therapeutic dose Prior administration wholebody radiation therapy within 12 week first plan therapeutic dose Prior external beam radiotherapy &gt; 25 % bone marrow Prior chemotherapy investigational compound and/or device within 30 day dosimetry dose Other active malignancy require additional treatment except superficial cutaneous neoplasm Karnofsky Performance Status &lt; 60 Clinically significant laboratory abnormality prior dose list protocol ( blood count abnormality , liver enzyme abnormality , renal dysfunction ) Medical history AIDS/HIV+ Active chronic alcohol abuse , chronic liver disease ( include liver metastasis ) , hepatitis A , B , C Known allergy iobenguane require medical intervention Receiving medication inhibits tumor uptake iobenguane I 131 Any condition , opinion investigator , may compromise safety compliance subject</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MIBG</keyword>
	<keyword>Azedra</keyword>
	<keyword>Rare neuroendocrine tumor</keyword>
	<keyword>Iobenguane I 131</keyword>
	<keyword>Progenics</keyword>
</DOC>